Perrigo (PRGO) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Perrigo (PRGO) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Perrigo | 1.93 Bn | 1.53 Bn | 313.90 Mn | 106.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -204.38% |
| Mar 28, 2026 | -66.06% |
| Dec 31, 2025 | 31.73% |
| Sep 27, 2025 | -57.75% |
| Jun 28, 2025 | -240.56% |
| Mar 29, 2025 | -80.79% |
| Dec 31, 2024 | 48.91% |
| Sep 28, 2024 | 12.06% |
| Jun 29, 2024 | -27.03% |
| Mar 30, 2024 | -27.23% |
| Dec 31, 2023 | 66.54% |
| Sep 30, 2023 | 81.21% |
| Jul 1, 2023 | -26.21% |
| Apr 1, 2023 | -26.80% |
| Dec 31, 2022 | -19.79% |
| Oct 1, 2022 | -69.18% |
| Jul 2, 2022 | -26.46% |
| Apr 2, 2022 | -26.35% |
| Dec 31, 2021 | -31.55% |
| Oct 2, 2021 | 58.00% |